{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-21-018477","form_type":"8-K","ticker":"CSBR","cik":"0000771856","company_name":"CHAMPIONS ONCOLOGY, INC.","filed_at":"2021-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.734537+00:00","generated_at":"2026-06-29T04:21:22.493742+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Champions Oncology Q1 revenue record $11.3M, up 18% YoY; non-GAAP op income $422k","bullets":["Record quarterly revenue of $11.3M, +17.9% YoY, driven by larger studies and platform expansion.","GAAP operating loss of $175k; non-GAAP operating income of $422k, excluding $280k stock comp and $317k D&A.","Gross margin improved to 52.0% from 44.1% as more lab work was performed internally.","Cash position $4.0M with no debt; net cash from operations $216k in the quarter.","Validated 6 therapeutic discovery targets; SaaS platform Lumin Bioinformatics adding new users."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-21-018477","json":"https://secwatch.observer/filing/0001628280-21-018477.json","markdown":"https://secwatch.observer/filing/0001628280-21-018477.md","text":"https://secwatch.observer/filing/0001628280-21-018477.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/771856/000162828021018477/0001628280-21-018477-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/771856/000162828021018477/csbr-20210913.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T04:21:22.493742+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}